Shattuck Labs Bolsters Financials as SL-325 Nears Phase 2 Milestone
At 11:08 AM today, Shattuck Labs (NASDAQ: STTK) attracted attention in the healthcare sector, combining forward-looking financial guidance with meaningful R&D updates in its Q4 and full-year 2025 results. The company’s Phase 1 trial for SL-325, a potential first-in-class DR3 blocking antibody, is approaching completion and promises new data in Q2 2026, keeping investors focused on upcoming clinical catalysts.
Cash Position Remains Strong, Runway into 2029
Shattuck's latest capital raise, drawing $21.4 million through an at-the-market offering in Q1 2026, contributed to a preliminary cash balance of $94.5 million as of February 28, 2026. This war chest, inclusive of the new capital, is projected to fund operations into 2029—assuming no further capital raises and based on current development plans.
| Period | Cash & Cash Equivalents (in millions) |
Short-Term Investments (in millions) |
Total |
|---|---|---|---|
| Dec 31, 2025 | $54.19 | $23.87 | $78.06 |
| Feb 28, 2026 (Prelim.) | - | $94.50 | |
This strong financial base came not just from steady fundraising but also from disciplined expense management. R&D expenses for 2025 dropped 48% compared to the prior year, largely due to discontinuation of SL-172154 and workflow reductions, offset in part by advancing SL-325 into clinical development.
SL-325: Critical Data Coming, Pipeline Expands
SL-325 is positioned as the first DR3 blocking antibody to reach human trials. Shattuck expects to share detailed safety, tolerability, PK, and receptor occupancy data from Phase 1 in Q2 2026, and to initiate Phase 2 for Crohn’s disease in Q3 2026—clear near-term milestones. Meanwhile, the company’s bispecific DR3 antibody program is entering IND-enabling studies, with target and preclinical data disclosures on deck for the first half of 2026.
R&D and Net Losses Decrease as Focus Sharpens
| Metric | Q4 2025 | Q4 2024 | FY 2025 | FY 2024 |
|---|---|---|---|---|
| R&D Expenses (M) | $9.06 | $15.40 | $35.27 | $67.21 |
| G&A Expenses (M) | $4.32 | $4.25 | $17.23 | $19.08 |
| Net Loss (M) | $(12.59) | $(18.68) | $(48.81) | $(75.41) |
Year over year, R&D and general administrative expenditures fell sharply—reflecting tighter operational discipline and strategic pipeline focus. Net losses similarly improved, with FY2025 seeing a narrowed loss of $48.8M versus $75.4M for FY2024.
Institutional Support and Operational Highlights
The recent equity raise brought T. Rowe Price above 10% ownership, suggesting institutional confidence in Shattuck’s long-term prospects. The team also expanded its clinical expertise with the appointment of Michael Choi, M.D., a veteran in inflammatory bowel disease drug development, as VP of Clinical Development.
Upcoming Catalysts for Investors to Watch
- Phase 1 SL-325 data: Q2 2026
- Phase 2 (Crohn’s Disease initiation): Q3 2026
- Bispecific program preclinical update: H1 2026
- Industry conference presentations: March 8-11, 2026 (Leerink Global Healthcare Conference)
What’s Next for Shattuck?
With enough cash to reach potentially pivotal data readouts and a sharpened focus on its lead programs, Shattuck Labs is setting up for a decisive year ahead. Investors may want to track clinical results for SL-325, the emerging bispecific pipeline, and management commentary at upcoming scientific conferences to gauge how these bets on immune-mediated disease therapies could shape the company’s future.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI